Understand the source comparison
Joint Pain Peptides Men Over 40 Active: Clinical Comparison
BPC-157 VEGF upregulation, FAK-paxillin pathway activation. Promotes angiogenesis and collagen synthesis 250–500 mcg daily, subcutaneous or intramuscular 2–4 weeks for tendon/ligament symptoms Acute tendinopathy, ligament sprains, joint capsule damage Most mec
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, FAK-paxillin pathway activation. Promotes angiogenesis and collagen synthesis
- 250–500 mcg daily, subcutaneous or intramuscular
- 2–4 weeks for tendon/ligament symptoms
- Acute tendinopathy, ligament sprains, joint capsule damage
- Most mechanistically validated for localized tissue repair in active populations
- Thymalin
- T-cell modulation, systemic cytokine regulation. Reduces baseline inflammatory load
- 5–10 mg per cycle, typically 10-day protocols
- 7–14 days for systemic inflammation markers
- Chronic low-grade inflammation, immune system optimization in aging athletes
- Best choice when joint pain correlates with systemic inflammatory markers or frequent illness
- KPV
- NF-κB pathway inhibition. Blocks inflammatory gene expression at transcription level
- 500 mcg–1 mg daily, subcutaneous
- 3–5 days for acute flare symptom reduction
- Acute inflammatory flares, post-training joint swelling
- Fastest-acting anti-inflammatory peptide with minimal systemic suppression
- Cartalax
- Chondrocyte differentiation support. Promotes cartilage matrix synthesis
- 5–10 mg per cycle, 10–20 day protocols
- 4–6 weeks for cartilage-related symptoms
- Osteoarthritis, cartilage degeneration, chronic wear patterns
- Promising for cartilage health but requires longer observation periods than tendon-focused peptides